{"id":4340,"date":"2025-03-17T06:30:18","date_gmt":"2025-03-17T10:30:18","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2025-du-nanos\/"},"modified":"2026-09-24T00:05:46","modified_gmt":"2026-09-24T04:05:46","slug":"gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2025-du-nanos","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2025\/03\/17\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2025-du-nanos\/","title":{"rendered":"GenSight Biologics annonce des communications scientifiques sur LUMEVOQ\u00ae au Congr\u00e8s 2025 du NANOS"},"content":{"rendered":"\nParis, France, le lundi, 17 mars 2025, 7h30 CET<\/strong> \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui que de nouvelles donn\u00e9es et analyses scientifiques relatives \u00e0 la th\u00e9rapie g\u00e9nique LUMEVOQ\u00ae seront pr\u00e9sent\u00e9es lors du 51e Congr\u00e8s Annuel de la North American Neuro-Ophthalmology Society<\/em> (NANOS) qui se tient \u00e0 Tucson, Arizona, Etats-Unis, du 15 au 20 mars 2025.\n\nDes leaders d\u2019opinion (KOLs<\/em>) dans le domaine de la Neuropathie Optique H\u00e9r\u00e9ditaire de Leber (NOHL) partageront de nouvelles donn\u00e9es sur les facteurs pr\u00e9dictifs de r\u00e9ponse au traitement avec LUMEVOQ\u00ae<\/sup>, sur la comparaison des r\u00e9sultats du traitement par l’id\u00e9b\u00e9none et LUMEVOQ\u00ae<\/sup>, sur l’exp\u00e9rience r\u00e9elle avec LUMEVOQ\u00ae<\/sup> et sur les r\u00e9sultats \u00e0 long terme d’un traitement bilat\u00e9ral avec la th\u00e9rapie g\u00e9nique.\n\nPoster<\/u> : \u201c<\/em>Predictive Factors of Improved Final Visual Outcome in Patients with Leber Hereditary Optic Neuropathy Treated with Lenadogene Nolparvovec Gene Therapy<\/em>\u201d<\/em>\n
    \n \t
  • Pr\u00e9sent\u00e9 par : Robert C. Sergott, MD<\/strong>, Wills Eye Hospital, Philadelphie, Etats-Unis<\/li>\n \t
  • Poster Num\u00e9ro 209<\/li>\n \t
  • Date et heure : lundi 17 mars 2025, de 17h00 \u00e0 18h00 <\/strong>(MDT)<\/li>\n \t
  • Lieu : Arizona Ballroom 1-6<\/li>\n<\/ul>\n \n\nPoster<\/u> : \u201cEfficacy of Lenadogene Nolparvovec Gene Therapy Versus Idebenone: Two Matched Adjusted Indirect Comparisons\u201d <\/em>\n
      \n \t
    • Pr\u00e9sent\u00e9 par : Patrick Yu-Wai-Man, MD, PhD<\/strong>, Universit\u00e9 de Cambridge, Moorfields Eye Hospital, et l\u2019UCL Institute of Ophthalmology, Royaume Uni<\/li>\n \t
    • Poster Num\u00e9ro 186<\/li>\n \t
    • Date et heure : lundi 17 mars 2025, de 18h00 \u00e0 19h00 (MDT)<\/strong><\/li>\n \t
    • Lieu : Arizona Ballroom 1-6<\/li>\n<\/ul>\n \n\nPoster<\/u> : \u201cEfficacy and Safety of Lenadogene Nolparvovec Gene Therapy for Leber Hereditary Optic Neuropathy in the Real-Life Setting\u201d<\/em>\n
        \n \t
      • Pr\u00e9sent\u00e9 par : Mark L. Moster, MD<\/strong>, Wills Eye Hospital, Philadelphie, Etats-Unis<\/li>\n \t
      • Poster Num\u00e9ro 12<\/li>\n \t
      • Date et heure : dimanche 16 mars 2025, de 14h00 \u00e0 15h00 <\/strong>(MDT)<\/li>\n \t
      • Lieu : Arizona Ballroom 1-6<\/li>\n<\/ul>\n \n\nPr\u00e9sentation plate-forme<\/u> : \u201cLong-Term Outcomes of Bilateral Injection of Lenadogene Nolparvovec Gene Therapy for Leber Hereditary Optic Neuropathy\u201d<\/em>\n
          \n \t
        • Pr\u00e9sent\u00e9 par : Nancy J. Newman, MD<\/strong>, Emory University School of Medicine, Atlanta, Etats-Unis<\/li>\n \t
        • Plate-forme Scientifique Session 1<\/li>\n \t
        • Date et heure : lundi 17 mars 2025, de 11h45 \u00e0 12h00 <\/strong>(MDT)<\/li>\n \t
        • Lieu : Tucson Ballroom<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"

          Paris, France, le lundi, 17 mars 2025, 7h30 CET \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui que de nouvelles donn\u00e9es et analyses scientifiques relatives […]<\/p>\n","protected":false},"author":10,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[],"news-topic":[73],"news-type":[74,75],"post-year":[],"class_list":["post-4340","post","type-post","status-publish","format-standard","hentry","category-communiques-de-presse-financiers","news-topic-gs010-lumevoq","news-type-product-candidates","news-type-clinical"],"acf":[],"yoast_head":"\nGenSight Biologics annonce des communications scientifiques sur LUMEVOQ\u00ae au Congr\u00e8s 2025 du NANOS - GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2025\/03\/17\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2025-du-nanos\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics annonce des communications scientifiques sur LUMEVOQ\u00ae au Congr\u00e8s 2025 du NANOS - GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Paris, France, le lundi, 17 mars 2025, 7h30 CET \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui que de nouvelles donn\u00e9es et analyses scientifiques relatives […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2025\/03\/17\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2025-du-nanos\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-17T10:30:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-24T04:05:46+00:00\" \/>\n<meta name=\"author\" content=\"Arthus Moulin-Fournier\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Arthus Moulin-Fournier\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2025\\\/03\\\/17\\\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2025-du-nanos\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2025\\\/03\\\/17\\\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2025-du-nanos\\\/\"},\"author\":{\"name\":\"Arthus Moulin-Fournier\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/ae14918d0ec7c587d729420ef3ca5c18\"},\"headline\":\"GenSight Biologics annonce des communications scientifiques sur LUMEVOQ\u00ae au Congr\u00e8s 2025 du NANOS\",\"datePublished\":\"2025-03-17T10:30:18+00:00\",\"dateModified\":\"2026-09-24T04:05:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2025\\\/03\\\/17\\\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2025-du-nanos\\\/\"},\"wordCount\":379,\"articleSection\":[\"Communiqu\u00e9 de presse Financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2025\\\/03\\\/17\\\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2025-du-nanos\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2025\\\/03\\\/17\\\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2025-du-nanos\\\/\",\"name\":\"GenSight Biologics annonce des communications scientifiques sur LUMEVOQ\u00ae au Congr\u00e8s 2025 du NANOS - GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2025-03-17T10:30:18+00:00\",\"dateModified\":\"2026-09-24T04:05:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/ae14918d0ec7c587d729420ef3ca5c18\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2025\\\/03\\\/17\\\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2025-du-nanos\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2025\\\/03\\\/17\\\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2025-du-nanos\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2025\\\/03\\\/17\\\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2025-du-nanos\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics annonce des communications scientifiques sur LUMEVOQ\u00ae au Congr\u00e8s 2025 du NANOS\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/ae14918d0ec7c587d729420ef3ca5c18\",\"name\":\"Arthus Moulin-Fournier\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/eace44d269d162de11a066bf28b6d0de50aec912351357046a1db52e59b9cbf9?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/eace44d269d162de11a066bf28b6d0de50aec912351357046a1db52e59b9cbf9?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/eace44d269d162de11a066bf28b6d0de50aec912351357046a1db52e59b9cbf9?s=96&d=mm&r=g\",\"caption\":\"Arthus Moulin-Fournier\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics annonce des communications scientifiques sur LUMEVOQ\u00ae au Congr\u00e8s 2025 du NANOS - GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2025\/03\/17\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2025-du-nanos\/","og_locale":"fr_FR","og_type":"article","og_title":"GenSight Biologics annonce des communications scientifiques sur LUMEVOQ\u00ae au Congr\u00e8s 2025 du NANOS - GenSight Biologics","og_description":"Paris, France, le lundi, 17 mars 2025, 7h30 CET \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui que de nouvelles donn\u00e9es et analyses scientifiques relatives […]","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2025\/03\/17\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2025-du-nanos\/","og_site_name":"GenSight Biologics","article_published_time":"2025-03-17T10:30:18+00:00","article_modified_time":"2026-09-24T04:05:46+00:00","author":"Arthus Moulin-Fournier","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Arthus Moulin-Fournier","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2025\/03\/17\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2025-du-nanos\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2025\/03\/17\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2025-du-nanos\/"},"author":{"name":"Arthus Moulin-Fournier","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/ae14918d0ec7c587d729420ef3ca5c18"},"headline":"GenSight Biologics annonce des communications scientifiques sur LUMEVOQ\u00ae au Congr\u00e8s 2025 du NANOS","datePublished":"2025-03-17T10:30:18+00:00","dateModified":"2026-09-24T04:05:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2025\/03\/17\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2025-du-nanos\/"},"wordCount":379,"articleSection":["Communiqu\u00e9 de presse Financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2025\/03\/17\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2025-du-nanos\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2025\/03\/17\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2025-du-nanos\/","name":"GenSight Biologics annonce des communications scientifiques sur LUMEVOQ\u00ae au Congr\u00e8s 2025 du NANOS - GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2025-03-17T10:30:18+00:00","dateModified":"2026-09-24T04:05:46+00:00","author":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/ae14918d0ec7c587d729420ef3ca5c18"},"breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2025\/03\/17\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2025-du-nanos\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2025\/03\/17\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2025-du-nanos\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2025\/03\/17\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2025-du-nanos\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics annonce des communications scientifiques sur LUMEVOQ\u00ae au Congr\u00e8s 2025 du NANOS"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/ae14918d0ec7c587d729420ef3ca5c18","name":"Arthus Moulin-Fournier","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/eace44d269d162de11a066bf28b6d0de50aec912351357046a1db52e59b9cbf9?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/eace44d269d162de11a066bf28b6d0de50aec912351357046a1db52e59b9cbf9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/eace44d269d162de11a066bf28b6d0de50aec912351357046a1db52e59b9cbf9?s=96&d=mm&r=g","caption":"Arthus Moulin-Fournier"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/4340","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=4340"}],"version-history":[{"count":0,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/4340\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=4340"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=4340"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=4340"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=4340"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=4340"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=4340"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=4340"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}